1. Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe.
- Author
-
Grom AA, Canna SW, Abu-Arja RF, Sinha R, Peixoto L, Cannizzaro E, Chandrakasan S, Driest K, Marsh R, Neven B, Onel K, Prahalad S, Prockop S, Quartier P, Roth J, Schulert G, Silva JMF, Wall D, and Zeilhofer U
- Subjects
- Humans, Europe, North America, Registries, Lung Diseases therapy, Hematopoietic Stem Cell Transplantation adverse effects
- Abstract
It has been increasingly recognized that there is a subset of patients with refractory systemic JIA, who have failed all available medications and may benefit from HSCT. The increasing experience with HSCT in SJIA, suggests that despite the complicated post-HSCT course, short-term, the transplanted patients either achieved SJIA remission or reduced burden of disease. Longer follow-up, however, is needed to better define the long-term outcomes. The discussion at the NextGen 2022 conference was focused on the optimal timing for the procedure, the need for a good control of inflammatory SJIA activity prior to HSCT, and the role of the reduced intensity conditioning regimens as there was a remote concern that such regimens might increase the risk of SJIA relapse after the transplantation. There was unanimous agreement about the importance of long-term registries to address these questions., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF